Research led by Memorial Sloan Kettering Cancer Center (MSK) is shedding new light on how ovarian cancer evolves—insights that could help researchers develop more effective treatment strategies.

In A Nutshell High-throughput drug screening identified rigosertib as highly selective for ovarian cancer cells. Alone, ...

While ovarian cancer is known as the 'silent killer' due to its vague symptoms, it's essential to be aware of the signs - ...

An unusual DNA structure may hold the key to treating one of the deadliest cancers affecting women, which claims more than ...

Early fallopian tube cell changes were found in a high‑risk patient. A live tissue bank and organoid system will help explore ...

A new FDA application for relacorilant shows promising survival benefits in treating platinum-resistant ovarian cancer, ...

Dr. Claire Thompson, a Consultant Gynaecological Oncologist, explains the causes of ovarian cancer and the genetic link that ...

Glucagon-like peptide-1 (GLP-1) receptor agonists significantly enhance overall survival in patients with ovarian cancer, ...

The response rate was higher in those with a KRAS mutation at 44%, compared to 17% in KRAS wild-type patients.

Ovarian cancer symptoms can be vague and ill-defined, leading to the creation of a catch-all acronym - BEAT. Dr. Thompson is ...

The CDK2 inhibitor INCB123667 showed positive efficacy and safety signals in platinum-resistant/refractory ovarian cancer.